Astrazeneca (AZN) Change in Cash (2010 - 2023)

Astrazeneca's Change in Cash history runs 12 years deep, the most recent figure standing at -$321.0 million for Q2 2023.

• In Q2 2023, Change in Cash rose 62.1% year-over-year to -$321.0 million; the TTM figure through Jun 2023 stood at -$2.0 billion (up 40.93% YoY), while the FY2025 annual figure was $223.0 million, up 293.91% from the prior year.
• Change in Cash was -$321.0 million for Q2 2023 at Astrazeneca, down from -$144.0 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of -$144.0 million in Q1 2023 to a low of -$1.7 billion in Q1 2020.
• Historically, Change in Cash has averaged -$655.4 million across 5 years, with a median of -$676.0 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Change in Cash surged 88.42% in 2021, then sank 253.55% in 2022.
• A 5-year view of Change in Cash shows it stood at -$757.0 million in 2019, then slumped by 118.15% to -$1.7 billion in 2020, then soared by 88.42% to -$191.2 million in 2021, then sank by 342.98% to -$847.0 million in 2022, then soared by 62.1% to -$321.0 million in 2023.
• The last three Change in Cash figures came in at -$321.0 million (Q2 2023), -$144.0 million (Q1 2023), and -$847.0 million (Q2 2022), per Business Quant data.